Side-by-side comparison of AI visibility scores, market position, and capabilities
New York specialty ingredients (NYSE: IFF) at $11.48B 2024 net sales, EBITDA +16%; flavors/fragrances + N&B health/biosciences ($26B 2021 acquisition), 2025 guidance 1-4% growth competing with Givaudan and dsm-firmenich.
International Flavors & Fragrances Inc. (IFF) is a New York City, New York-based global specialty ingredients company — publicly traded on the New York Stock Exchange (NYSE: IFF) as an S&P 500 Materials component — creating and manufacturing flavors, fragrances, enzymes, probiotics, food ingredients, cosmetic actives, and pharmaceutical excipients for consumer goods companies, food manufacturers, beverage companies, and pharmaceutical firms through approximately 20,000 employees in 110 countries. In fiscal year 2024, IFF reported net sales of $11.48 billion and adjusted operating EBITDA growth of 16% to $2.21 billion, demonstrating improved profitability following the challenging integration of the DuPont Nutrition & Biosciences business (acquired 2021 for ~$26 billion in the largest transaction in IFF's history). For 2025, IFF guided 1-4% comparable currency-neutral sales growth, with continued margin improvement as the integration synergies are realized. CEO Jon Erik Fyrwald leads the company through its integration and portfolio optimization phase. IFF operates across four segments: Nourish (flavors, functional ingredients, proteins, food and beverage innovation), Scent (fine fragrances, consumer fragrances, cosmetic actives), Health & Biosciences (enzymes, microbiome, probiotics, animal nutrition), and Pharma Solutions (pharmaceutical excipients and delivery systems) — serving every major category of consumer products from food and beverages to personal care, household products, and medicine.
Cambridge/Colorado trapped-ion quantum computing (Honeywell majority; $625M+/$5B valuation Jun 2024); Helios Nov 2025 at 98 physical/48 logical qubits with 99.9975% fidelity serving Amgen/BMW/JPMorgan competing with IBM Quantum.
Quantinuum is a Cambridge, UK and Broomfield, Colorado-based integrated quantum computing company — majority owned by Honeywell (NASDAQ: HON) with $625+ million in total funding including a $300 million round led by JPMorgan Chase at a $5 billion valuation in June 2024 — operating the world's most accurate commercial quantum computers using trapped-ion technology combined with quantum software from Cambridge Quantum. In November 2025, Quantinuum launched Helios, its third-generation quantum computer featuring 98 physical qubits and 48 logical error-corrected qubits with 99.9975% single-qubit gate fidelity and 99.921% two-qubit gate fidelity — the highest-accuracy general-purpose commercial quantum computer commercially available. Serving enterprise customers including Amgen (drug discovery), BMW Group (materials simulation), JPMorgan Chase (financial optimization), and SoftBank Corp. (AI acceleration), Quantinuum was formed in November 2021 through the merger of Honeywell Quantum Solutions and Cambridge Quantum Computing. CEO Ilyas Khan.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.